<DOC>
	<DOCNO>NCT00380406</DOCNO>
	<brief_summary>The purpose study determine whether gonadotropin release hormone agonist ( medical therapy ) protect ovarian failure reproductive age woman undergo sterilize chemotherapy .</brief_summary>
	<brief_title>PROtecting Ovaries Fertility During Chemotherapy - The PROOF Trial</brief_title>
	<detailed_description>Fertility preservation define maintenance one 's ability reproduce . The hypothesis study medical treatment ( GnRHa ) help female cancer patient , receive sterilize chemotherapy , preserve ovarian function therefore fertility . This study feasibility trial drug ( GnRHa ) v placebo female cancer patient receive gonadotoxic chemotherapy age 18 38 wish participate . The objective feasibility trial determine feasibility definitive study answer question also define require parameter need design definitive study observable difference ovarian failure drug placebo group . The protocol follow propose definitive trial small sample size . This pilot study conduct Ottawa Hospital Regional Cancer Centre/Division Reproductive Medicine Department Obstetrics Gynecology , University Ottawa Cancer Centre Southeastern Ontario/Division Reproductive Medicine Department Obstetrics Gynecology , University Ottawa . The planned trial intervention trimonthly ( every 3 month ) administration depot GnRHa ( Leuprolide acetate ( LA ) 11.25 mg intramuscularly ) placebo . Injections would start prior initiation chemotherapy , luteal phase menstrual cycle precede chemotherapy , continue cessation chemotherapy ( maximum 6 month 2 injection ) . Since adjuvant/curative chemotherapy patient enrol , chemotherapy last maximum six month . Subjects randomize , concealed allocation , either GnRHa placebo . Subjects investigator blind intervention administer . Inclusion criterion : Women 1. age 18 38 ; 2. undergoing gonadotoxic ( sterilize ) curative/ adjuvant chemotherapy early stage disease ; 3. provide informed consent . All subject enrol Ottawa Hospital Regional Cancer Institute ( OHRCC ) Cancer Center South Eastern Ontario Kingston General Hospital ( CCSEO ) . Gonadotoxic chemotherapy include alkylating / anthracycline agent eg . cyclophosphamide . Exclusion criterion : Women ; 1. advance stage disease and/or whose median survival expect less 6 month 2. cancer ovary , uterus , fallopian tube ; 3. clinical biochemical evidence diminish ovarian reserve ( recent shortening cycle &amp; lt ; 24 day menses , age &amp; gt ; 38 , elevate serum FSH ( follicular stimulate hormone ) &amp; gt ; 15 IU/L , low antral follicle count ( AFC- number follicle less 10 mm day 2 3 natural menses ) baseline pelvic ultrasound ( &amp; lt ; 5 ) elevate day 2 3 estradiol ( &amp; gt ; 280 pmol/ml ) ; 4. previously receive chemotherapy abdominal/pelvic radiation plan receive abdomino/pelvic radiation ; 5. pregnant ; 6. contraindication intramuscular injection ; 7 ) history fracture secondary to/or document osteoporosis . Outcomes : Subjects assess baseline , monthly ( adverse effect ) active intervention , 0 , 3 , 6 , 9 , 12 month post cessation chemotherapy treatment ( GnRHa/ placebo ) predictor ovarian reserve . The primary outcome protection ovarian failure 12 month post chemotherapy . This measured resumption regular menstrual cycle ( every 24 -35 day ) documentation ovulation biochemistry ( progesterone level ) minimum three month . Secondary outcome include sonographic ( biophysical ) biochemical marker ovarian reserve .</detailed_description>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Women : 1. age 18 38 ; 2. undergoing gonadotoxic ( sterilize ) curative/ adjuvant chemotherapy early stage disease ; 3. provide informed consent . All subject enrol Ottawa Hospital Regional Cancer Institute ( OHRCC ) Cancer Center South Eastern Ontario Kingston General Hospital ( CCSEO ) . Women : 1. advanced stage disease and/or whose median survival expect less 6 month 2. cancer ovary , uterus , fallopian tube ; 3. clinical biochemical evidence diminish ovarian reserve ( recent shortening cycle &amp; lt ; 24 day menses , age &amp; gt ; 38 , elevate serum FSH ( follicular stimulate hormone ) &amp; gt ; 15 IU/L , low antral follicle count ( AFC number follicle less 10 mm day 2 3 natural menses ) baseline pelvic ultrasound ( &amp; lt ; 5 ) elevate day 2 3 estradiol ( &amp; gt ; 280 pmol/ml ) ; 4. previously receive chemotherapy abdominal/pelvic radiation plan receive abdomino/pelvic radiation ; 5. pregnant ; 6. contraindication intramuscular injection ; 7. history fracture secondary to/or document osteoporosis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Gonadotropin release hormone agonist</keyword>
	<keyword>GnRH</keyword>
	<keyword>Fertility</keyword>
	<keyword>Fertility preservation</keyword>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>